tradingkey.logo
tradingkey.logo
Search

Oncolytics Biotech® Announces Type C FDA Meeting To Discuss Single-Arm Registrational Pathway For Pelareorep In Anal Cancer

ReutersApr 6, 2026 1:04 PM

- Oncolytics Biotech Inc ONCY.O:

  • ONCOLYTICS BIOTECH® ANNOUNCES TYPE C FDA MEETING TO DISCUSS SINGLE-ARM REGISTRATIONAL PATHWAY FOR PELAREOREP IN ANAL CANCER

  • ONCOLYTICS BIOTECH INC - SCHEDULES TYPE C FDA MEETING ON APRIL 16, 2026 FOR PELAREOREP IN ANAL CANCER

  • ONCOLYTICS BIOTECH INC - MEETING TO DISCUSS SINGLE-ARM PIVOTAL STUDY OF PELAREOREP IN SECOND-LINE AND LATER SCAC

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Tradingkey
KeyAI